Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 109Endometrial Neoplasms 16Neoplasm Metastasis 10Polycystic Ovary Syndrome 9Ovarian Neoplasms 7Neoplasms 7Advanced Breast Cancer 5Triple Negative Breast Neoplasms 4Prostatic Neoplasms 4Fallopian Tube Neoplasms 4Recurrence 3Infertility 3Carcinoma, Intraductal, Noninfiltrating 3Breast Neoplasms, Male 3Squamous Cell Carcinoma of Head and Neck 2Progesterone Resistance 2Neoplasms by Site 2Hereditary Sensory and Autonomic Neuropathies 2Head and Neck Neoplasms 2HR+/HER2- Breast Cancer 2Estrogen Receptor-positive Breast Cancer 2Endometrial Hyperplasia 2Cystadenocarcinoma, Serous 2Carcinoma, Non-Small-Cell Lung 2Breast Diseases 2Breast Cancer Metastatic 2Breast Cancer Female 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Small Cell Lung Carcinoma 1

Interventions

Specimen Handling 9Tamoxifen 8Radiotherapy 6exemestane 3Radiation Dose Hypofractionation 3Radiation 3Letrozole 3Anastrozole 3Surveys and Questionnaires 2Sentinel Lymph Node Biopsy 2Radiotherapy, Intensity-Modulated 2Radiotherapy, Conformal 2Patient Navigation 2Observation 2Metformin 2Mastectomy 2Magnetic Resonance Spectroscopy 2Genetic Testing 2Biopsy 2trastuzumab biosimilar HLX02 1ruxolitinib 1poly ICLC 1palbociclib 1fezolinetant 1elacestrant 1afimoxifene 1abemaciclib 1Trastuzumab 1Testosterone 1Tablets 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Intraductal, Noninfiltrating × Letrozole × 1 year × Clear all
NCT01272037 2026-06-03

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
5,018 enrolled 14 charts
Breast

Carcinoma, Intraductal, Noninfiltrating

NCT06075953 2026-05-22

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
400 enrolled
Breast

Carcinoma, Intraductal, Noninfiltrating

NCT06218303 2026-03-12

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

University of Pittsburgh

Phase 1 Recruiting
50 enrolled
Breast

Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡